CD274 and non-small cell lung carcinoma: For example, in a recent 2023 study by Yang et al., combining cTMB with dynamic ctDNA response and plasma PD-L1 levels significantly improved the predictive accuracy for ICI benefit in NSCLC patients, outperforming single-biomarker models [76].